BioNTech SE(BNTX)Earnings, Financials & Key RatiosBioNTech SE (BNTX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current operating loss of $672.0 million in 2026Q1 and the absence of a clear path to commercial profitability suggest significant execution risk for long-term investors.
BioNTech SE (BNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
BioNTech SE (BNTX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $2.28vs $2.52+9.5% | $136Mvs $207M-34.2% |
| Q2 2026 | Mar 10, 2026 | $0.38vs $0.22-72.7% | $1.1Bvs $902M+18.1% |
| Q4 2025 | Nov 3, 2025 | $0.14vs $1.12+87.5% | $1.8Bvs $844M+110.9% |
| Q3 2025 | Aug 4, 2025 | $1.82vs $2.69+32.3% | $307Mvs $178M+72.7% |
Recent stock market news and headlines for BioNTech SE (BNTX)
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt on Wednesday.
Key metrics vs top competitors for BioNTech SE (BNTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $94.29 | $23.84B | -18.30 | 0.2% | -39.59% | -5.65% | — | |
| $79.77 | $31.64B | -10.99 | -39.23% | -143.55% | -36.73% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $7.60 | $216.02M | -3.17 | -51.43% | -173.47% | -36.55% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — |
BioNTech SE (BNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioNTech SE (BNTX) stock FAQ — growth, dividends, profitability & financials explained
BioNTech SE (BNTX) reported $2.80B in revenue for fiscal year 2025. This represents a 4443% increase from $61.6M in 2017.
BioNTech SE (BNTX) grew revenue by 0.2% over the past year. Growth has been modest.
BioNTech SE (BNTX) reported a net loss of $1.26B for fiscal year 2025.
BioNTech SE (BNTX) has a return on equity (ROE) of -5.7%. Negative ROE indicates the company is unprofitable.
BioNTech SE (BNTX) generated $1.26B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
